Opko Health, Inc. (OPK) Earnings Call Analysis
NASDAQ · Healthcare · Diagnostics & Research
Earnings Reports
-
OPK Q2 2026: Operating Loss Narrows $53M as Diagnostics Restructuring and Pipeline Execution Take Hold
July 28, 2026
-
OPK Q1 2026: Regeneron Milestone Potential Tops $1B as MODX Pipeline Advances
April 29, 2026
-
OPK Q4 2025: $1B+ Regeneron Milestone Upside, Diagnostics Refocus Drives Margin Reset
February 27, 2026
-
OPK Q3 2025: $192M Oncology Asset Sale Reshapes Diagnostics, Fuels R&D and Buybacks
October 29, 2025
-
Opko Health (OPK) Q2 2025: Oncology Asset Sale Unlocks $225M, Refocuses Diagnostics for Profitability
July 31, 2025
-
OPK Q1 2025: $225M LabCorp Divestment Reshapes Diagnostics, Refocuses Pipeline
July 04, 2025